The North America Non-steroidal Anti-inflammatory Drugs Market is expected to witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Throughout the course of the forecast period, market expansion is anticipated to be aided by the rising prevalence of pain-related conditions such as arthritis. For instance, the CDC estimates that around 1 in 4 adults in the United States, or roughly 58.5 million individuals, has been diagnosed with arthritis. Compared to males, women (23.5%) are more likely to have this arthritis than men (18.1 percent). As a result, it is anticipated that the increased incidence of arthritis will support growth during the projection period.
Age-related disorders as CVDs, cancer, arthritis, chronic pain, diabetes, and others are more common in the senior population. Thus, it is anticipated that the market will expand as the global elderly population rises. For instance, a report from the Administration on Ageing (AoA) estimates that the number of Americans 65 and over was approximately 54.1 million in 2019, or more than 16 percent of the country's total population. There were roughly 24.1 million men and about 30 million women among them. By 2040, there will be 21.6 percent of this population in the United States. Therefore, it is anticipated that the growth will be fueled by the ongoing increase in the geriatric population over the forecast period.
Due to reasons like the developed healthcare industry with a big number of well-known firms, significant investment, and the demand for more potent and secure medications, among others, this region with the greatest market for anti-inflammatory pharmaceuticals. In addition, the high income per capita, increase in doctor visits, and breakthroughs in research due to high financing are among the factors boosting the regional market's expansion. The herb arnica is found in several nations of the region. The flowers are being utilized medicinally to treat conditions like osteoarthritis, surgery, sore throats, and other conditions that cause pain. Arnica is frequently applied to treat bleeding, swelling, and bruises.
The US market dominated the North America Non-steroidal Anti-inflammatory Drugs Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $6,376.7 Million by 2028. The Canada market is poised to grow at a CAGR of 7.6% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 6.6% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Disease Indication, the market is segmented into Arthritis, Migraine, Ophthalmic Diseases and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.
Throughout the course of the forecast period, market expansion is anticipated to be aided by the rising prevalence of pain-related conditions such as arthritis. For instance, the CDC estimates that around 1 in 4 adults in the United States, or roughly 58.5 million individuals, has been diagnosed with arthritis. Compared to males, women (23.5%) are more likely to have this arthritis than men (18.1 percent). As a result, it is anticipated that the increased incidence of arthritis will support growth during the projection period.
Age-related disorders as CVDs, cancer, arthritis, chronic pain, diabetes, and others are more common in the senior population. Thus, it is anticipated that the market will expand as the global elderly population rises. For instance, a report from the Administration on Ageing (AoA) estimates that the number of Americans 65 and over was approximately 54.1 million in 2019, or more than 16 percent of the country's total population. There were roughly 24.1 million men and about 30 million women among them. By 2040, there will be 21.6 percent of this population in the United States. Therefore, it is anticipated that the growth will be fueled by the ongoing increase in the geriatric population over the forecast period.
Due to reasons like the developed healthcare industry with a big number of well-known firms, significant investment, and the demand for more potent and secure medications, among others, this region with the greatest market for anti-inflammatory pharmaceuticals. In addition, the high income per capita, increase in doctor visits, and breakthroughs in research due to high financing are among the factors boosting the regional market's expansion. The herb arnica is found in several nations of the region. The flowers are being utilized medicinally to treat conditions like osteoarthritis, surgery, sore throats, and other conditions that cause pain. Arnica is frequently applied to treat bleeding, swelling, and bruises.
The US market dominated the North America Non-steroidal Anti-inflammatory Drugs Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $6,376.7 Million by 2028. The Canada market is poised to grow at a CAGR of 7.6% during (2022 - 2028). Additionally, The Mexico market is expected to witness a CAGR of 6.6% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Oral, Topical and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Disease Indication, the market is segmented into Arthritis, Migraine, Ophthalmic Diseases and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., GlaxoSmithKline PLC, Bayer AG, Teva Pharmaceuticals Industries Ltd., Eli Lilly And Company, Sanofi S.A., AstraZeneca PLC, Viatris, Inc., and Merck & Co., Inc.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
- Oral
- Topical
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Disease Indication
- Arthritis
- Migraine
- Ophthalmic Diseases
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Dr. Reddy’s Laboratories Ltd.
- Pfizer, Inc.
- GlaxoSmithKline PLC
- Bayer AG
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly And Company
- Sanofi S.A.
- AstraZeneca PLC
- Viatris, Inc.
- Merck & Co., Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. North America Non-steroidal Anti-inflammatory Drugs Market by Route of Administration
Chapter 5. North America Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel
Chapter 6. North America Non-steroidal Anti-inflammatory Drugs Market by Disease Indication
Chapter 7. North America Non-steroidal Anti-inflammatory Drugs Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- Pfizer, Inc.
- GlaxoSmithKline PLC
- Bayer AG
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly And Company
- Sanofi S.A.
- AstraZeneca PLC
- Viatris, Inc.
- Merck & Co., Inc.
Methodology
LOADING...
